DNTH - CIK 0001690585
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported revenue of $2.04M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $2.04M | -67.3% |
| FY 2024 | $6.24M | +120.6% |
| FY 2023 | $2.83M | -56.0% |
| FY 2022 | $6.42M | +334.8% |
| FY 2021 | $1.48M | - |
| FY 2019 | $0.00 | - |
| FY 2018 | $0.00 | - |
| FY 2017 | $0.00 | - |
| FY 2016 | $0.00 |
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported revenue of $2.04M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2016 and fiscal 2025, Dianthus Therapeutics, Inc. /DE/'s revenue grew from $0.00 to $2.04M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |